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Background: Ocular tuberculosis (TB) can affect nearly every ocular tissue, leading to a variety of vision-threatening
clinical manifestations. The goal of this study is to estimate the degree, duration, and causes of visual impairment in
eyes affected by ocular TB.
Results: This was a retrospective study of patients diagnosed as ocular TB based on polymerase chain reaction
(PCR) for Mycobacterium tuberculosis complex. We applied the World Health Organization definition of visual
impairment (VI) to affected eye(s), instead of better-seeing eye. Best-corrected visual acuity (BCVA) of <6/18 and
≥6/60 in the affected eye was classified as moderate VI and <6/60 and ≥3/60 as severe VI. Data collected included
presenting and final BCVA of affected eyes and the worst BCVA during the study period. Sixty-one eyes of 40
patients were analyzed. Twenty-five patients (52.1%) had bilateral disease. The mean worst BCVA and mean final
BCVA (logMAR) were 1.26 ± 0.87 and 0.61 ± 0.85, respectively, and their difference was highly significant (p < 0.0001,
Friedman test). The median worst and final BCVA results were 1.30 (range 0.0 to 3.0) and 0.20 (range 0.0 to 3.0),
respectively. The mean duration of follow-up was 98.34 ± 81.81 weeks. Moderate and severe VIs were seen in
14 (22.9%) and 12 (19.7%) eyes, respectively, during the course of follow up. Twenty eyes (32.8%) had BCVA of
<3/60. Moderate VI or worse was most commonly seen in eyes with multifocal serpiginoid choroiditis (n = 6; 100%),
retinal vasculitis (n = 25; 80.6%), and panuveitis (n = 12; 80%). The mean duration of visual loss was 25.2 ± 42.37 weeks
(median 6.43 weeks, range 0 to 206.42 weeks). Vitreous hemorrhage, complicated cataract, and macular scarring
were the common causes of VI.
Conclusion: Ocular TB can result in prolonged visual impairment, more commonly in patients with posterior uveitis
or panuveitis.
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Ocular tuberculosis (TB) is among the common causes
of infectious uveitis in endemic countries [1]. It has a
wide variety of clinical manifestations affecting nearly
every ocular tissue. These include anterior uveitis, inter-
mediate uveitis, retinal vasculitis, infectious multifocal
serpiginoid choroiditis (MSC), choroidal tuberculoma,
subretinal abscess, scleritis, and optic neuritis [2]. How-
ever, the diagnosis of ocular TB is often delayed since it
is difficult to differentiate these clinical manifestations
from other infectious and noninfectious conditions [3].* Correspondence: eyetalk@gmail.com
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in any medium, provided the original work is pAdditionally, the paucibacillary nature of ocular TB pre-
cludes definitive diagnosis in majority of cases [2,4].
Thus, delay in the initiation of specific antitubercular
therapy (ATT) can lead to recurrent or chronic inflam-
mation and thereby long-standing visual impairment in
the affected eyes [3].
Recent reports on ocular TB have focused on its histo-
pathological features, clinical manifestations, diagnostic
criteria, and role of ancillary tests like tuberculin skin
test (TST), interferon gamma release assay (IGRA), and
chest radiography [4-7]. However, there is no large study
on the extent and causes of visual impairment (VI) in this
condition. The present study aims to elucidate this vital
yet unexplored aspect of ocular TB. We have attempted to
evaluate VI in each eye affected by ocular TB (instead ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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order to obtain the complete picture of visual morbidity
in this disease.
Methods
We reviewed medical records of all patients with clin-
ically suspected ocular TB, evaluated at our institute
between December 2011 and November 2012. We in-
cluded patients who either had a definitive diagnosis
of ocular TB by polymerase chain reaction (PCR) or
showed a positive response to antitubercular therapy,
i.e., no clinical recurrence 6 months after initiation of
antitubercular therapy. The study was approved by the
institutional review board and adhered to the tenets of
Declaration of Helsinki. We followed a standard proto-
col for all ocular TB patients. All patients had a detailed
recording of history including exposure to active pul-
monary tuberculosis. Clinical evaluation included best-
corrected visual acuity (BCVA), intraocular pressure,
slit lamp evaluation, and indirect ophthalmoscopy. The
clinical manifestations and anterior chamber inflam-
mation were classified on the basis of Standardization
of Uveitis Nomenclature (SUN) Working Group re-
commendations, while vitreous haze was graded by the
National Eye Institute system [8,9].
All patients were investigated for complete hemogram,
erythrocyte sedimentation rate, chest x-ray, TST, and
ELISA for HIV; while specific investigations were or-
dered to rule out infectious (other than TB) and noninfec-
tious conditions that cause similar clinical manifestations.
Patients who were clinically suspected with ocular TB
(based on above evaluation) and had any grade of anterior
chamber cells were considered for anterior chamber para-
centesis for PCR test for Mycobacterium tuberculosis.
We used a multitarget PCR assay targeting the IS6110,
MPB64, and protein B gene targets of M. tuberculosis
[10]. All patients with clinically suspected ocular TB (in-
cluding PCR-negative patients) were treated with ATT
consisting of isoniazid 5 mg/kg/day, rifampicin 450 mg/
day if body weight was ≤50 kg and 600 mg/day if body
weight was >50 kg, ethambutol 15 mg/kg/day, and pyrazi-
namide 25 to 30 mg/kg/day for initial 2 months. There-
after, rifampicin and isoniazid were used for another
4 months. The duration of ATT was restricted to 6 months
based on World Health Organization (WHO) recommen-
dations for extrapulmonary TB [11]. Corticosteroid ther-
apy was administered (generally starting on the same day
as ATT) by one or more routes - topical, periocular, intra-
vitreal, oral, or intravenous, depending on the anatomical
location or severity of inflammation. Patients were gene-
rally followed up at weeks 2, 6, 12, 24, and 36 and in be-
tween or thereafter, depending on the response to therapy.
The following information was extracted from the pa-
tients' records: age; gender; laterality; clinical diagnosis;investigation results including TST, IGRA, chest radiog-
raphy, and PCR; ocular complications; BCVA; intraocu-
lar pressure; inflammatory status at each visit; treatment
details (ATT and corticosteroids); additional procedures;
and duration of follow-up. The presenting BCVA, worst
BCVA during the study period (in case it was different
from presenting BCVA), and final BCVA of each eye
were noted. For the purpose of our study, VI was defined
by applying WHO guidelines to eyes affected by ocular
TB [12]. Thus, BCVA of <6/18 and ≥6/60 in the affected
eye was classified as moderate VI and <6/60 and ≥3/60
as severe VI. Eyes with BCVA of <3/60 were classified
separately. We did not define legal blindness, since only
unilateral VI was analyzed. The duration of visual loss
was calculated from the visit with BCVA of <6/18 until
it improved to ≥6/18. In case of multiple episodes of
inflammation, the duration of visual loss in individual
episodes was added up to obtain the total duration. The
primary cause of decreased visual acuity at each visit
was also noted.
Statistical analysis was done using the InStat statistical
software version Win 3.0× (GraphPad Software Inc., CA,
USA). The impact of gender and laterality on visual loss
was analyzed using Mann–Whitney test. Wilcoxon
matched-pairs signed-ranks test was used to analyze the
impact of treatment. Friedman test (nonparametric re-
peated measures ANOVA) was used to compare pre-
senting, worse, and final visual acuity. Snellen visual
acuity was approximated to logMAR values for statistical
analysis, wherever required.
Results
Sixty-one eyes of 40 patients were analyzed. The patients
were nearly equally divided between bilateral (n = 21;
52.5%) and unilateral (n = 19; 47.5%) cases. The mean
age of patients was 34.4 ± 12.11 years (range 6 to
60 years). Twenty-seven (67.5%) were males and 13
(32.5%) were female patients. The mean duration of
follow-up was 98.34 ± 81.81 weeks.
The distribution of patients among various clinical
patterns of ocular TB is given in Table 1. Retinal vascu-
litis (n = 31 eyes) and panuveitis (n = 15 eyes) were the
two most common patterns of ocular TB in our series.
Overall, the mean worst and final BCVA results in our
patients were 1.324 ± 0.89 and 0.698 ± 0.91, respectively.
The difference between mean final and mean worst
BCVA was found to be highly significant (p < 0.0001,
Friedman test). Fourteen eyes (22.9%) had moderate VI
and twelve eyes (19.7%) had severe VI at some point of
follow-up. Twenty eyes (32.8%) had BCVA of <3/60 du-
ring this period. Table 1 also mentions various grades and
duration of VI noted in each clinical pattern. Moderate VI
or worse was most commonly seen in eyes with multifocal
serpiginoid choroiditis (n = 6; 100%), retinal vasculitis










Total number of eyes 5 3 31 6 15 1 61
Mean presenting BCVA ± SD 0.62 ± 0.95 0.73 ± 0.49 0.85 ±0.91 0.55 ± 0.65 0.97 ± 0.79 0.4 ± 0.0 0.82 ± 0.82
Median (range) 0.30 (0.0 to 2.30) 0.50 (0.40 to 1.30) 0.60 (0.0 to 3.0) 0.3 (0 to 1.80) 0.90 (0 to 2.30) 0.4 (0.4to 0.4) 0.50 (0.0 to 3.0)
Mean worst BCVA ± SD 0.84 ± 1.21 1.46 ± 1.34 1.36 ± 0.91 1.02 ± 0.54 1.17 ± 0.69 2.5 ± 0.0 1.26 ± 0.87
Median (range) 0.30(0.20 to 3.0) 0.90 (0.50 to 3.0) 1.30 (0 to 3.0) 0.75 (0.5 to 1.8) 1.30 (0.0 to 2.30) 2.5 (2.5 to 2.5) 1.30 (0.0 to 3.0)
Mean final BCVA ± SD 0.72 ± 1.28 1.2 ± 1.56 0.71 ± 0.88 0.1 ± 0.06 0.49 ± 0.63 0.1 ± 0.0 0.61 ± 0.85
Median (range) 0.20 (0.10 to 3.0) 0.30 (0.30 to 3.0) 0.30 (0.30 to 3.0) 0.10 (0.0 to 0.20) 0.20 (0.0 to 2.30) 0.1 (0.1 to 0.1) 0.20 (0 to 3.0)
Number of eyes with moderate
visual loss (BCVA <6/18 and ≥6/60)
P - - 5 1 3 - 9
W - 1 6 3 4 - 14
F - - 6 - 3 - 9
Number of eyes with severe
visual loss (BCVA <6/60 and ≥3/60)
P - 1 4 - 3 - 8
W - - 8 - 4 - 12
F - - 4 - 1 - 5
Number of eyes with BCVA <3/60 P 1 - 7 1 4 - 13
W 1 1 11 2 4 1 20
F 1 1 4 - 1 - 7
Mean duration of visual loss
(weeks) ± SD
5.91 ± 13.22 0.38 ± −0.66 36.31 ± 53.37 8.42 ± 8.81 21.27 ± 28.69 11.29 ± 0.0 25.2 ± 42.37
Median (range) 0.0 (0 to 29.57) 0.0 (0.0 to 1.142) 13.57 (0 to 206.42) 5.92 (0 to 24.57) 11.14 (0.0 to 86.571) 11.29 (11.29 to 11.29) 6.43 (0 to 206.42)
Mean duration of follow up
(weeks) ± SD
65.23 ± 37.13 123.71 ± 170.97 111.06 ± 88.78 59.071 ± 12.63 90.86 ± 73.68 141.42 ± 0.0 98.34 ± 81.81
Median (range) 41(36.71 to 105.86) 25(25 to 321.14) 63.71(12.42 to 301.71) 63.71 (37 to 69.29) 47.14(21 to 216.42) 141.42 (0 to 141.42) 63.71 (12.43 to 321.14)
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in anterior uveitis (n = 1; 20.0%). The mean presenting
visual acuity was worst for panuveitis and best for
intermediate uveitis. Overall, the mean duration of vi-
sual loss was 25.2 ± 42.37 weeks (median 6.43 weeks,
range 0 to 206.42 weeks) for all eyes, which is lowest
for anterior uveitis (median 0 weeks) and highest for
retinal vasculitis (median 13.57 weeks).
Various ocular complications and the additional proce-
dures required for management of such complications
are given in Table 2. Vitreous hemorrhage, complicated
cataract (both n = 10), and macular scarring (n = 9)
were the most commonly observed causes of visual
loss. Vitreous surgery was the most commonly required
additional procedure in our patients. We did not find
any influence of age (p = 0.24) or gender (p = 0.31) on
VI caused by ocular TB.
Discussion
Our study analyzes the extent, causes, and duration of
VI in eyes affected by ocular TB. Since nearly half our
patients had unilateral disease, we preferred to study VI
in each affected eye instead of the better eye BCVA, thus
getting a wider perspective of visual morbidity in ocular
TB. Importantly, unilateral VI (moderate to severe) has
been shown to have a measurable impact to health-
related quality of life, besides subjective visual function
and binocular and stereo acuity [13,14].
The mean age of patients in our series was 34.4 ±
12.11 years, which indicates the impact of ocular TB on
the productive age group of our population. The clinical
presentation in our patients was predominantly posterior
uveitis (retinal vasculitis and MSC) or panuveitis, unlike
an earlier report on presumed ocular TB, in which
nearly half (45.1%) of the patients had anterior orTable 2 Complications and their in various clinical categories







Pupillary membrane 1 -
Complicated cataract 1 1
Secondary glaucoma 1 -
Vitreous hemorrhage - -
Epiretinal membrane - -
Cystoid macular edema - -
Tractional retinal detachment - -
Optic atrophy - -
Macular scarring/inflammation - -
Cataract surgery - 1
Glaucoma surgery 1 -
Vitreous surgery - -
Retinal photocoagulation - -intermediate uveitis [5]. This could have influenced the
degree of VI noted in our series. In general, patients
with posterior uveitis or panuveitis had lower mean
worst visual acuity than those with anterior or inter-
mediate uveitis. Our results match the previous studies
on visual loss in uveitis, though they followed different
criteria for classification of visual loss [15-17]. Moderate
VI or worse (BCVA < 6/18) was also seen more in pa-
tients with posterior uveitis or panuveitis than anterior/
intermediate uveitis. Overall, 46 of 61 eyes (75.4%) had
moderate VI or worse, during the course of follow up.
The most common causes of visual loss in our study
were vitreous hemorrhage, complicated cataract, and
macular scarring/ inflammation. Vitreous hemorrhage
and CME were commonly seen in eyes with retinal
vasculitis, macular scarring was mostly associated with
MSC, while complicated cataract was mostly seen in
panuveitis. The incidence of CME in our study was
lower than that reported for uveitis in general, as we had
fewer patients with anterior or intermediate uveitis, and
fluorescein angiography and optical coherence tomog-
raphy were not done routinely in all patients [15-17].
Vitreous hemorrhage was treated with retinal photo-
coagulation or vitreous surgery as required and often
resulted in marked improvement in visual acuity. Eyes
with MSC also improved markedly after treatment with
ATT and corticosteroid therapy. In general, the mean
VA across all categories of clinical presentations, im-
proved significantly (p < 0.0001), following ATT and vari-
ous ancillary treatments. Some eyes with complicated
cataract had not received cataract surgery until the last
follow-up, indicating that there was further scope of im-
provement in mean final VA. Thus, our study highlights
the effect of ocular complications, the visual morbidity










- - - - 1
2 1 5 - 10
- - 1 - 2
9 - - 1 10
2 - - - 2
5 - 1 - 5
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1 - 2 - 3
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1 - 2 - 4
- - 1 - 2
9 - - - 9
4 - - - 4
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attributable to uveitis are often classified separately
without the causal diagnosis, leading to falsely low
values for uveitis blindness/VI [18].
We did not find any effect of age or gender on the de-
gree of visual impairment. A recent study on mycobac-
terial ocular inflammation associated delay in diagnosis
and age older than 50 years with profound visual loss
[3]. We could not calculate the duration of disease for
most patients, as the time of onset prior to referral was
not clearly documented in all patients. Also, the number
of patients in each clinical category was not large
enough for statistical analysis of their effect on visual
impairment, although, as stated earlier, posterior uveitis
or panuveitis generally had worse visual acuity. Finally,
we could not separately analyze the impact of ATT on
visual impairment in ocular TB, since all patients re-
quired simultaneous management of ocular inflamma-
tion with corticosteroids and of various complications
like vitreous hemorrhage, cataract, and glaucoma.
Conclusions
Ocular TB and its complications cause moderate to
severe visual impairment in majority of affected eyes,
especially in eyes with posterior uveitis or panuveitis.
Appropriate management of this condition can signifi-
cantly recover the visual loss.
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